PeriVision registers VR- & AI-based eye testing platform VisionOne with US FDA

PeriVision, a groundbreaking spin-off from the University of Bern and the University Hospital Bern, has announced the FDA registration of its VisionOne platform.

Originating as a project aimed at democratizing access to advanced eye care, PeriVision has now bridged a crucial gap in ophthalmological diagnostics and treatment with VisionOne. Introduced last year, the platform has been designed to simplify eye examinations through the use of portable VR headsets, offering a modern solution to the cumbersome and often inaccessible traditional methods. With VisionOne, professionals can not only conduct eye tests more efficiently but also access and analyze results through a sophisticated cloud platform. The backend is powered by AI algorithms that refine eye tests, ensure quality control, automate assistance, and deliver crucial insights for clinical decisions.

The achievement of FDA registration marks a significant validation of PeriVision’s dedication to adhering to the highest standards of safety, efficacy, and quality in medical software. Dr. Ernest Cavin, a board member with extensive experience in ophthalmology, highlighted the registration as a culmination of rigorous research, development, and collaboration with top institutions.

Real-world solutions addressing global health challenges

VisionOne’s AI, VR, and eye-tracking technologies address the pressing needs within the ophthalmology community. Specifically targeting the diagnosis and monitoring of glaucoma—a leading cause of irreversible blindness affecting over 80 million people globally—VisionOne aims to revolutionize visual field testing. In the press release, Dr. Kevin Gillmann, PeriVision’s Chief Medical Officer and a glaucoma specialist, underscores the device’s registration as just the beginning. The company aspires to expand its portfolio with a comprehensive suite of eye tests and AI tools designed to enhance clinic productivity, disease management, and patient experiences.

With FDA approval now in hand, PeriVision can introduce its state-of-the-art care to healthcare providers. The company is set to showcase VisionOne at the upcoming Vision Expo East in New York, signaling its readiness to transform the landscape of ophthalmological diagnostics and care.